Table 1.
Patient characteristics (n = 189)
| Characteristic | Value |
|---|---|
| Age (years)* | 63 (54, 72) |
| Male | 85 (45%) |
| Cancer diagnosis | |
| Lung, gastric, hepatocellular, or melanoma | 49 (26%) |
| Sarcoma or other carcinoma | 38 (20%) |
| Breast, prostate, renal cell, thyroid, myeloma, or lymphoma | 102 (54%) |
| Bone metastasis | |
| Solitary | 54 (29%) |
| Multiple | 135 (71%) |
| Fracture type | |
| Completely broken | 83 (44%) |
| Impending | 106 (56%) |
| ECOG performance status | |
| ≤ 2 | 91 (48%) |
| ≥ 3 | 98 (52%) |
| Lymph node metastasis | 34 (18%) |
| Visceral metastasis | 113 (60%) |
| Albumin (g/dL)* | 4.0 (3.5, 4.4) |
| Absolute lymphocyte count (K/μL)* | 1.0 (0.6, 1.5) |
| Calcium (g/dL)* | 9.2 (8.7, 9.7) |
| GFR (mL/min/1.73 m2)* | 96 (75, 114) |
| Hemoglobin (g/dL)* | 11.4 (10.1, 12.9) |
| Surgeon estimate of survival (months)* | 8 (4, 12) |
| Survival > 3 months | 131 (69%) |
| Survival > 12 months | 78 (41%) |
Values are expressed as median, with interquartile range in parentheses; the remaining values are expressed as frequency, with percentage in parentheses; ECOG = Eastern Cooperative Oncology Group; GFR = estimated glomerular filtration rate.